CCTG MAC.7 | SWOG 0226 clinical trial published in the NEJM
Published:Category: Publications
Updated results of the CCTG MAC.7 | SWOG 0226 study have recently been published in the New England Journal of Medicine. Long-term results of a phase III trial showed that women with metastatic hormone-sensitive breast cancer lived nearly 8 months longer with the addition of fulvestrant (Faslodex) to first-line anastrozole (Arimidex).
Read MoreTrial Activation: PR20 (NCT03784755)
Published:Category: Trials
PR.20: A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON] has been activated.
Eligibility: Male, aged 18 years or older; Histologically-proven oligometstatic adenocarcinoma of the prostate and no evidence of small cell cancer; Stage: IV (newly diagnosed at presentation or relapse after curative intent therapy); M1 disease with </= 5 metastases; N1 disease can be included as site of metastases only in p
Supplementary Training Requirement: Due April 30
Published:Category: Group updates
All participants at our member sites will be required to attest to the completion of this one-time training requirement by April 30, 2019.
Read MoreTrial Activation: ALC.6 (A041501)
Published:Category: Group updates
ALC.6 (A041501), A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL, has been centrally activated.
About the trial
Read MoreSudbury oncologist says clinical trials help treat different types of cancers
Published:Category: News
Dr Lacey Pitre is an Oncologist and CCTG researcher at the Northeast Cancer Centre in Sudbury, she spoke at a press conference earlier this month to help kick off the Canadian Cancer Society's Daffodil Campaign in Northern Ontario.
Read MoreTrial Closure: IND215
Published:Category: Trials
The IND215 trial has been permanently closed.
IND215 is a Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC Who are Receiving Standard Chemotherapy Regimens.
Primary publication citation
Goffin JR, Nicholas G, Mates M, Tu D, Chen E, Laurie SA, Juergens R, Robinson A, Goss G, Reaume M, S, Christink K, Maize C, MacFarlan S, X, Ritter H, Seymour L, Bradbury PA Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advan
Read MoreMA36 study meets accrual targets
Published:Category: Trials
The MA36 study team would like to thank everyone who helped them reach the 34 patient accrual goal for this important study.
MA36 is a Randomised, Double-Blind, Parallel group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.
Read MoreCCTG Thoracic Disease Site Committee Radiation Oncology Co-Chair position
Published:Category: Group updates
Dr. Yee Ung will be stepping down as the CCTG radiation oncology co-chair of the thoracic disease site committee as of April 2019, and we are calling for applicants to this position.
The applicant should be a thoracic oncology staff radiation oncologist practicing in a CCTG member Institution in Canada, with international or national leadership experience in clinical trials.
Read More